Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2000, p. 639-642, Vol. 38, No. 2
Transmissible Diseases Department, American
Red Cross, Rockville, Maryland,1 and
Hospital Sírio Libanês, São Paulo,
Brazil2
Received 21 June 1999/Returned for modification 1 September
1999/Accepted 22 November 1999
The radioimmunoprecipitation assay (RIPA) has been used as a
confirmatory test in several ongoing and published studies of Trypanosoma cruzi in blood donors in the United States.
Despite its use as a confirmatory test, few studies are available
comparing RIPA to commercially available serologic test methods. Thus,
we compared RIPA with two indirect hemagglutination assays (Biolab Diagnostica SA, São Paulo, Brazil; Hemagen Diagnostics, Inc., Waltham, Mass.) and four different enzyme-linked immunosorbent assays
(Abbott Laboratories, Abbott Park, Ill.; Embrabio, São Paulo,
Brazil; Organon Teknika, São Paulo, Brazil; and Gull
Laboratories, Salt Lake City, Utah) using a panel of 220 serum
specimens from Brazilian blood donors with a range of T. cruzi antibody titers as determined by indirect
immunofluorescence assay (IFA). A titer of 1:20 was used as the
baseline for seropositivity. All IFA-negative serum specimens
(n = 19) were nonreactive on all tests. At a titer of
1:20 (n = 9), reactivity rates varied considerably
among the tests, with only the RIPA and the Organon and Gull assays
identifying reactive specimens. For specimens at a 1:40 titer
(n = 35), most assays identified at least 32 of 35 (91%) specimens as reactive, but the Biolab assay only identified 24 (69%). At higher titers (1:80, n = 56; 1:160,
n = 101) the assays were comparable, with the
exception of the Biolab assay, demonstrating rates of agreement with
IFA of
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Serologic Testing for Trypanosoma cruzi:
Comparison of Radioimmunoprecipitation Assay with Commercially
Available Indirect Immunofluorescence Assay, Indirect Hemagglutination
Assay, and Enzyme-Linked Immunosorbent Assay Kits
98%. Overall, when compared with several other test formats,
RIPA demonstrated equivalent or superior rates of agreement with
IFA-positive specimens across all titers examined. In particular, at
titers of >1:40, the RIPA compared favorably with other test methods currently in use, supporting its application as a confirmatory test, particularly in a research setting.
*
Corresponding author. Mailing address: Department of
Transmissible Diseases, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855. Phone: (301) 738-0608. Fax: (301) 738-0495. E-mail: leibyd{at}usa.redcross.org.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»